Hunt Lecture Legacy
The WHF-TK Hunt Lectureship was developed to honor Dr Hunt's legacy of research, mentoring and education by selecting awardees who have made major contributions or innovations to the field of science that could impact the field of wound research. The lectureship is currently 43% endowed. Please consider helping us fulfill the endowment today so Dr Hunt's legacy will be remembered and honored by future wound researchers through this unique lecture series.
The Wound Healing Foundation established the Thomas K. Hunt Endowed Lecture in 2013 to honor the legacy of Dr. Hunt and to inspire and educate wound healing researchers on related research innovations. The award is not limited to those who are directly involved in wound healing research, that is, consideration will be given to researchers who demonstrate the ability to bridge scientific gaps and cross boundaries through the use of basic physiology to understand healing processes in multiple organ systems.
TK Hunt children Tom Hunt Jr and Karyn Hunt Ellis at the 2019 WHF-Thomas K. Hunt Lecture
Honorary Hunt Lecturer George A. Brooks (center) with TK Hunt Children Tom and Karyn on either side, WHF Board and WHS President Sashwati Roy (3rd from left)
Tom Hunt Jr and Karyn Hunt Ellis with their father's friend, colleague and 2019 WHF-TK Hunt Lecturer George A Brooks and his wife Rosemary Agostini, MD
2018 Thomas K. Hunt Lecture.
WHF President Laura Parnell, TK Hunt 2018 Lecturer Elaine Fuchs, and WHF Board Member Elof Eriksson.
WHF Board Members and TK Hunt 2018 Lecturer Elaine Fuchs (pictured from L: Marjana Tomic-Canic, WHS Past President; Manuela Martins-Green, WHF Board Member; Laura Parnell, WHF President; Elaine Fuchs, TK Hunt 2018 Lecturer; Elof Eriksson, WHF Board Member; Paul Liu, WHF Secretary)
WHF President Laura Parnell and Elaine Fuchs, TK Hunt 2018 Lecturer.
Thomas K. Hunt at the 2017 WHF Hunt Lecture.
Additional characteristics of the WHF Thomas K. Hunt Lecture awardees may include, but are not limited to:
- Major contributions to scientific inquiry that is likely to advance the field of wound healing
- Technological innovations or mechanistic insight that can quantify or improve wound healing or its research
- Academic achievement through mentoring across disciplines
- Potential impact on wound research directions or therapies
Future awardees of the Thomas K. Hunt Lectureship are selected annually by the Wound Healing Foundation. The award will fund the travel, lodging, meeting registration and compensation. Awardees are also able to attend a special private annual luncheon with the Thomas K. Hunt lecturer. If you donate to this lecture or your company provides the endowment of this lectureship, your company may also participate in this unique activity. To help complete the endowment of this program, visit our donate page to make a donation today.
The Foundation is raising funds to support several endowed lectures to be given at the annual meeting of the Wound Healing Society. Lectures can be given by a clinical scientist and/or a basic scientist focused on improving wound care or wound healing. The goal of this campaign is $100,000 for each lecture to be endowed.
2021 Lecture - Randy Schekman, PhD
Randy Schekman, PhD
Department of Molecular and Cell Biology
UC Berkeley, Berkeley, CA
Dr. Randy Schekman is a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute. He studied the enzymology of DNA replication as a graduate student with Arthur Kornberg at Stanford University. His current interest in cellular membranes developed during a postdoctoral period with S. J. Singer at the University of California, San Diego. At Berkeley, he developed a genetic and biochemical approach to the study of eukaryotic membrane traffic. Among his awards are the Gairdner International Award, the Albert Lasker Award in Basic Medical Research and the Nobel Prize in Physiology or Medicine, which he shared with James Rothman and Thomas Südhof. He is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, a Foreign Associate of the Accademia Nazionale dei Lincei, a Foreign Associate of the Royal Society of London and an Honorary Academician of the Academia Sinica. In 1999, he was elected President of the American Society for Cell Biology. From 2002-2017, he served as Editor-in-Chief of the Annual Reviews of Cell and Developmental Biology. From 2006 - 2011 he served as Editor-in-Chief of the Proceedings of the NAS. In 2011, he founded and until 2019 served as the Editor-in-Chief of the Open Access journal, eLife, sponsored by the HHMI, Wellcome Trust and the Max Planck Society. Beginning in 2019, Schekman will lead an effort supported by the Sergey Brin Family Foundation to identify and support basic research on the mechanisms of Parkinson’s Disease initiation and progression (https://parkinsonsroadmap.org).
Schekman’s laboratory investigates the mechanism of membrane protein traffic in the secretory pathway in eukaryotic cells. His approach began with a genetic and biochemical dissection of the secretory pathway in the yeast, S.cerevisiae. His lab discovered the genes and proteins that assemble proteins into the endoplasmic reticulum membrane, package proteins into coated (COPII) transport vesicles and deliver vesicles by fusion at a target membrane. The genes and proteins his lab discovered in yeast have counterparts in all eukaryotes and have been implicated in several human genetic diseases. The evolutionary conservation of the pathway discovered in Schekman’s lab encouraged the biotechnology industry to use yeast as a platform for the production of clinically important human secreted proteins. Approximately one-third of the world supply of recombinant human insulin is made by secretion in yeast and the entire world supply of recombinant hepatitis b vaccine is made in vesicles produced in yeast. As hepatitis b infection is the major cause of liver cancer in the world, this vaccine promises to reduce the incidence of liver cancer by 90%. In recent years his lab has turned from yeast to mammalian cell culture to investigate aspects of human physiology and disease that are not readily studied in yeast.
Past WHF Thomas K Hunt Endowed Lecture Speakers are:
|2020||Margaret A. Liu, MD, DSchc, MDhc, FISV
Foreign Adjunct Professor at the Karolinska Institutet, Stockholm, Sweden
Adjunct Full Professor at the University of California, San Francisco
CEO PAX Therapeutics
View Lecturer Bio
Margaret A. Liu obtained an M.D. from Harvard Medical School, a B.A. in Chemistry, summa cum laude, from Colorado College, and passed the Epreuve pour le Diplôme d’Enseignement, à l’unanimité (judges’ unanimous decision), in piano from the Ecole Normale de Musique de Paris. She completed Internship and Residency in Internal Medicine and a Fellowship in Endocrinology, all at Massachusetts General Hospital/Harvard Medical School. Previous visiting, faculty, and adjunct faculty appointments were at the Massachusetts Institute of Technology, Harvard Medical School, and The University of Pennsylvania, respectively. Working with Prof. Herman Eisen, known for his seminal work on antibody binding, elucidating the T cell receptor sharpened her immunological skills while a Visiting Scientist at MIT. Later while at Merck, she worked closely with Dr. Maurice Hilleman, the legendary vaccinologist who developed more than 40 vaccines.
Use of gene-based vectors for the development of preventions and treatments for infectious diseases and cancer, specifically vaccines and immunotherapeutics is Dr. Liu’s expertise. Two of the technologies that she pioneered have now been developed by companies into licensed products: bispecific antibodies for cancer therapy, and DNA vaccines for veterinary applications and which are in numerous human clinical trials for vaccines (for example, one of the first COVID-19 vaccine clinical trials), gene therapy, and immunotherapy for cancer, autoimmune diseases, and allergy.
Dr. Liu currently is CEO of PAX Therapeutics, a nascent biotech company using gene delivery of VEGF to optimize healing of ligaments and tendons after surgical repair for rupture. She also consults in the fields of vaccines and immunotherapy for companies, universities, and non-governmental, scientific governmental organizations and international agencies such as WHO, and is a director at Ipsen Pharma. Previous roles included: Senior Director at Merck Research Laboratories, Vice President of Vaccines Research and Gene Therapy at Chiron Corporation, Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation, Vice-Chairman of Transgene, and Executive Vice-Chair of the International Vaccine Institute (IVI), an independent international organization with signatory countries in Seoul, Korea established by UNDP. Dr. Liu is a Foreign Adjunct Professor at the Karolinska Institutet in Stockholm and an Adjunct Full Professor at the University of California, San Francisco. She is the Chairman of the Board and President Emeritus of the International Society for Vaccines.
Dr. Liu has received numerous awards and honors including an NIH Physician Scientist Award. She was invited by the Nobel Committee to lecture in the Karolinska Research Lecture series, was named one of “The 50 Most Important Women in Science” by Discover magazine, has multiple patents, and has been selected for numerous honorary lectureships. She has also had the conferral of two honorary doctorates, the most recent being Medical Doctor honoris causa from the Karolinska Institutet, Stockholm, Sweden.
|2019||George A. Brooks, PhD
UC Berkeley, Berkeley, CA
Lactate Shuttling and Redox Signaling in Normal and Pathophysiology
View Lecturer Bio
As a collegiate athlete George Brooks was very much interested in understanding physiology and biochemistry to improve is time in the 440 and 880 yard runs. In that capacity Brooks had to manage lactic acidosis on a daily basis. When his competitive days were over he earned a Ph.D. in Exercise Physiology at the University of Michigan and subsequently took a post-doctoral fellowship in Muscle Biology and the University of Wisconsin. Dr. Brooks then joined the University of California Berkeley Faculty in July of 1971. At Cal Berkeley, Dr. Brooks retained an interest in understanding human performance during exercise and at high altitude, but he turned his attention his attention to studying basic metabolic processes to better understanding of human capabilities in health and disease.
In recent years, Dr. Brooks and colleagues developed two working hypotheses: "The Lactate Shuttle", and the "Crossover Concept." Research on the Lactate Shuttle has been to elucidate the pathways and controls of lactate (lactic acid) formation and removal before, during and after exercise. The work involved studies on animals and humans, the use of isotope tracers, muscle biopsies and cardiovascular, pulmonary and endocrine measurements. Along the way he and colleagues discovered that the body makes lactate all the time, and that endurance training develops the capacities to produce, remove and utilize lactate as a fuel energy source. Subsequently, studies of lactate shuttling have revealed three functions of lactate; lactate is a fuel energy source, the main gluconeogenic precursor, and a signaling molecule with autocrine, paracrine and endocrine functions. In fact, Dr. Brooks and colleagues demonstrated that lactate is favored as a fuel by working red muscle, heart, liver and brain. Along the way they also discovered that the muscle respiratory apparatus is comprised of a large network, a “mitochondrial reticulum” that doubles in mass in response to regular exercise because training which also increases the expression of hundred of genes.
For the last decade Dr. Brooks and others have appreciated translational value of Lactate Shuttle theory. Recent research shown that lactate is a favored brain fuel in injured as well as healthy persons and clinical trials are under way to improve outcomes in traumatic brain injury patients using lactate supplementation. Also, he and his colleagues noted similarities between metabolic responses in exercise and cancer; a feature of cancer cells being aerobic glycolysis and lactate production (i.e., the Warburg Effect) under fully aerobic conditions. Currently independent investigators and workers in pharma are attempting to control cancer cell proliferation by developing Lactate Shuttle blockers and inhibitors of MCT insertion into plasma membranes. Dr Brooks is also thought to be responsible for the aphorism "Tumors are wounds that don't heal". Similarly, Brooks’ journey into translational research inevitably brought him in contact with Thomas K. (TK) Hunt. As such, they spent many happy and challenging hours discussing, and teaching lactate metabolism in trauma and wound healing. In his semi-historical and biographical lecture Dr. Brooks will remind and inform about Lactate Shuttle theory and encourage others to translate theory into practice.
Dr Brooks he has published more than 200 peer-reviewed papers and has been cited over 31,000 times. He has also served on several NIH grant review panels, and was a member of the National Academy of Sciences panel that wrote the scientific report that is the base for our current dietary guidelines. Dr. Brooks received the Honor award from the American College of Sports Medicine in 2007, and the Honor award from the Exercise and Environmental Physiology Section of the American Physiological Society in 2014.
|2018||Elaine Fuchs, PhD
The Rockefeller University, NYC, NY
Coping with Stress: Stem Cells in Injury, Cancer and Inflammation
View Lecturer Bio
Elaine Fuchs is an Investigator at the Howard Hughes Medical Institute at the Rockefeller University, where she is the Rebecca C. Lancefield Professor of Mammalian Cell Biology and Development. Her lecture kicked off the WHS Annual Scientific Meeting at the Symposium for Advanced Wound Care on April 25, 2018 in Charlotte, North Carolina.
Elaine Fuchs, PhD
The largest reservoirs of adult stem cells reside in skin. They continually renew the body’s protective barrier, regenerate hair in cyclical bouts, and repair surface wounds. Dr. Fuchs studies where stem cells come from and how they make and repair tissue throughout life. She explores how stem cells communicate with immune, dermal, and other cells in their environment and how this communication malfunctions in aging and cancers.
Dr. Fuchs' lab couples in vitro studies with classical genetics, RNAi, and CRISPR-Cas technologies in mice to study the biology of skin stem cells. Her research employs high throughput genomic analyses, live imaging, cell biology, and functional approaches to unravel the molecular pathways that determine the normal balance between stem cell maintenance and differentiation and how this goes awry in cancers. Her team is learning how stem cells establish unique chromatin landscapes and programs of gene expression and how this shifts in response to changes in their local environment. They have found that activating signals from neighboring cells instruct skin stem cells when to make hair and when to repair injuries. Conversely, inhibitory cross talk tells the stem cells when to stop making tissue and rest. This work is accelerating the development of therapeutics to enhance wound repair.
By elucidating the positive and negative signaling pathways that need to be turned on and off at the right time and place for adult skin stem cells to become activated to regenerate tissue, her group began to employ genetic methods to investigate what happens when these signals are deregulated. They learned cancer cells hijack the basic mechanisms that enable stem cells to replenish dying cells and to repair wounds.
A major focus is on squamous cell carcinomas, among the most common and life threatening of human cancers worldwide. The group first used high throughput genomics to delineate the features of so-called “cancer stem cells.” They then devised technology that permits high throughput functional screens for oncogenes and tumor suppressors in mice. By identifying mutations that selectively fuel cancer growth and showing that these alterations also occur in related human cancers, Dr. Fuchs hopes her research will lead to new therapeutics that target cancer stem cells without affecting tissue stem cells.
By studying early steps in malignancy, the group discovered that invading blood vessels and associated inflammatory cells transmit aberrant signals. Nearby tumor-initiating cells respond by reducing proliferation, invading the stroma, and resisting chemotherapy. Further away, tumor stem cells grow faster but show greater sensitivity to drugs. This leads to differences in the behavior of stem cells within the developing tumor arising from heterogeneity in the tumor microenvironment rather than variations in genetic mutations.
How do these stromal aberrations affect the transcriptional and epigenetic programs of stem cells during tumor progression? How do these changes confer drug resistance and how do they affect epithelial polarity, adhesion, and invasiveness within the tumor? Does the epigenetic heterogeneity in tumor stem cells that arises from local variations in the stroma contribute to subsequent genetic heterogeneity within cancers? What is the importance of immune cell cross talk with stem cells in wound repair versus cancer? As the group answers these questions experimentally, they will continue to uncover new links to understanding the process of wound repair, as well as tumor progression and metastasis.
|2017||Napoleone Ferrara, MD
University of California, San Diego
Anti-Angiogenic Therapy: From Bench To Clinic
View Lecturer Bio and 2017 Presentation
Dr. Ferrara earned his M.D. degree in 1981 from the University of Catania Medical School in Italy. After completing his postdoctoral research at the University of California, San Francisco, he joined Genentech Inc. in 1988. It is there where he spent nearly 25 years working on the isolation, molecular cloning and biological characterization of VEGF-A which resulted in the development of bevacizumab, the first anti-angiogenic agent to be approved by the FDA for cancer therapy. His research also led to the development of ranibizumab, which has been FDA-approved for the treatment of multiple intraocular neovascular disorders. In December 2012, Dr. Ferrara joined the University of California, San Diego as a Distinguished Professor of Pathology, Distinguished Adjunct Professor of Ophthalmology & Pharmacology, and Senior Deputy Director for Basic Science of the Moores Cancer Center. He plans to continue his research focusing on the biology of angiogenesis and the identification of its regulators.
Dr. Ferrara has authored over 300 scientific publications, which have been cited over 130,000 times according to Google Scholar. He is also the recipient of numerous scientific awards, including the AACR Cain Memorial Award, the Lefoulon-Delalande-Institut de France Prize, the Passano Award, the General Motors Cancer Research Award, the ASCO Science of Oncology Award, the Pezcoller Foundation-AACR International Award, the Lasker-deBakey Clinical Medical Research Award, the Janssen Award for Biomedical Research, the Economist Innovation Award, the Breakthrough Prize in Life Sciences, the Antonio Champalimaud Vision Award and the Gairdner Foundation International Award. Dr. Ferrara has been an elected member of the National Academy of Sciences, USA since 2006 and most recently became an elected member of the National Academy of Medicine in 2015.
This lecture was held at the WHS meeting on Wednesday, April 5, 2017 from 8:15-9:15AM at the San Diego Convention Center in San Diego, California. Dr. Ferrara's scientific and intellectual contributions on the biology and regulation of angiogenesis were stimulating for meeting attendees and thus positively impacted future wound healing research.
Anti-Angiogenic Therapy: From Bench To Clinic
|2016||Robert Langer, Sc.D.
Massachusetts Institute of Technology
Biomaterials and biotechnology: From the discovery of the first angiogenesis inhibitors to the development of controlled drug delivery systems and the foundation of tissue engineering
View Lecturer Bio
Robert Langer, Sc.D. from MIT has accepted the Foundation's invitation to be the 2016 WHF-Thomas K. Hunt Endowed Lecture Speaker. Dr Langer is one of only 13 Institute Professors at MIT; the highest honor that can be awarded to a faculty member. His h-index of 211 is the highest of any engineer in history and he has over 1,080 issued and pending patents worldwide. His patents have been licensed or sublicensed to over 300 companies. He served as Chairman of the FDA’s highest advisory Science Board from 1999-2002. Dr. Langer is also one of very few individuals ever elected to the Institute of Medicine of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors. He is one of four living individuals to have receive both the United States National Medal of Science and the United States National Medal of Technology and Innovation. In 2015, Dr. Langer received the Queen Elizabeth Prize for Engineering. He has also received the Charles Stark Draper Prize (considered the engineering Nobel Prize), Albany Medical Center Prize, the Wolf Prize for Chemistry, the Millennium Technology Prize, the Priestley Medal (highest award of the American Chemical Society), the Gairdner Prize, the Kyoto Prize and the Lemelson-MIT prize, for being “one of history’s most prolific inventors in medicine.” He holds 25 honorary doctorates including honorary degrees from Harvard and Yale.
This lecture was held at the Wound Healing Society meeting on Wednesday, April 13, 2016 from 11:45-12:45PM at the Georgia World Congress Center in Atlanta, Georgia. Dr. Langer's scientific and intellectual contributions on innovative research to develop new drugs, devices, biomaterials and delivery systems proved to be stimulating for meeting attendees and thus positively impacted future wound healing research.
|2015||Leroy Hood, MD, PhD.
Institute for Systems Biology
Proactive P4 Medicine: Catalyzing a Revolution in Healthcare through a Longitudinal, Digital-Age 100,000 Person Wellness Project
View Lecturer Bio
Leroy Hood, M.D., Ph.D. from the Institute for Systems Biology has accepted the Foundation's invitation to be the WHF-Thomas K. Hunt Endowed Lecture Speaker in 2015. Dr. Hood is a pioneer in the systems approach to biology and medicine. His research has focused on the study of molecular immunology, biotechnology and genomics. Dr. Hood’s professional career began at Caltech, where he and his colleagues developed the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer–– four instruments that paved the way for the successful mapping of the human genome. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, The Accelerator, Rosetta, and Integrated Diagnostics. He has coauthored numerous textbooks, including a book on the human genome project, The Code of Codes. He is the recipient of numerous awards, including the Lasker Award for Studies of Immune Diversity, the Kyoto Prize in advanced technology, the NAE 2011 Fritz J. and Delores H. Russ Prize and most recently, the 2011 National Medal of Science (awarded in 2013). In addition to having received 17 honorary degrees from prestigious universities in the US and abroad, Dr. Hood has published more than 750 peer reviewed papers. Hood is now pioneering new approaches to P4 medicine—predictive, preventive, personalized and participatory, and most recently, has embarked on creating a P4 pilot project on 100,000 well individuals, that is transforming healthcare. To learn more about Dr Hood, please visit http://www.systemsbiology.org/leroy-hood.
This lecture was the opening session of the Wound Healing Foundation meeting on Wednesday, April 29, 2015 from 8:15-9:15 AM at The Henry B. Gonzales Convention Center in San Antonio, Texas. The Foundation believes Dr. Hood's scientific and intellectual contributions on the systems approach to biology and medicine was stimulating for meeting attendees and thus positively impacted future wound healing research.
|2014||Robert A. Weinberg, Ph.D., presented by Jordan A. Krall, Ph.D.
Whitehead Institute for Biomedical Research
Tumor stromal interactions and malignant progression
View Lecturer Bio
Robert A. Weinberg, Ph.D. from the Whitehead Institute for Biomedical Research has accepted the Foundation's invitation to be the WHF-Thomas K. Hunt Endowed Lecture Speaker in 2014. Dr. Weinberg is a pioneer in cancer research focusing on epithelial and stromal cells as well as invasion and metastasis. He is a founding member of the Whitehead Institute and has numerous accolades including the prestigious National Medal of Science (1997), Wolf Prize in Medicine (2004) and many others. To learn more about Dr Weinberg, please visit http://wi.mit.edu/people/faculty/weinberg.
This lecture was the opening session of the Wound Healing Foundation meeting on Wednesday, April 23, 2014 from 8:30-9:30 AM at The Gaylord Palms Hotel and Convention Center in Orlando, Florida. Dr. Weinberg's scientific and intellectual contributions of bridging cancer and wound healing was stimulating and fascinating for meeting attendees and positively impacted their research upon returning to their labs and clinics.
|2013||Thomas K Hunt, MD
Professor Emeritus, University of California San Francisco
Lactate, Oxygen and Wound Healing
View Lecturer Bio
Dr. Thomas K. Hunt, the first President of the Wound Healing Foundation, is a highly regarded clinician, scientist, and mentor who made major contributions to the field of wound healing. His seminal contributions have largely focused on the importance of tissue oxygen perfusion and its measurement along with a host of other clinical and laboratory studies directed at improving wound healing for individuals. His reputation as a clinician, scientist, and mentor spring from his clinical acumen, insightful discoveries, and passion for developing the next generation of clinicians and scientists. The book “Fundamentals of Wound Management” written by Dr. Hunt and Dr. J. E. Dunphy is known to generations of wound healing clinicians and scientists. Dr. Hunt has over 400 published papers but perhaps his proudest accomplishment is the mentoring of numerous clinicians and scientists in his laboratory at the University of California San Francisco.
Dr. Hunt received his B. S. in Biochemistry from Harvard University in 1952 and graduated from Harvard Medical School in 1956. He completed his internship at Boston City Hospital; followed by service as a captain in the Medical Corps; and then completed his surgical residency at the University of Oregon Medical School. It was during a fellowship at the University of Glasgow that he began to investigate the role of oxygen in wound healing. Then in 1965, he joined the Department of Surgery at the University of California San Francisco where he remained for his entire career becoming a Professor Emeritus in 2001.